Bangkok Genomics Innovation PCLBKK:BKGI -2.88%45 EBITDA Margin % is 24.27% as of Dec. 2025, which is 18% above its 10-year median of 20.49. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 70.44% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bangkok Genomics Innovation PCL EBITDA Margin % Related Terms
Bangkok Genomics Innovation PCL EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a EBITDA Margin % of 24.27% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 18% above median its historical median of 20.49. Over the past decade, Bangkok Genomics Innovation PCL's EBITDA Margin % has ranged from 16.25 to 30.93. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #60 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 29.6%.
Is Bangkok Genomics Innovation PCL's EBITDA Margin % too high?
Bangkok Genomics Innovation PCL's current EBITDA Margin % of 24.27% is 18% above median its 10-year median of 20.49. Over the past 10 years, this metric has ranged from a low of 16.25 to a high of 30.93. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Bangkok Genomics Innovation PCL's value of 24.27% is 385.4% above this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #60 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #60 out of 203 companies for EBITDA Margin %. This puts Bangkok Genomics Innovation PCL in the upper half of its industry. The industry median EBITDA Margin % is 5.00. Bangkok Genomics Innovation PCL's value of 24.27% is 385.4% above this benchmark. Historically, Bangkok Genomics Innovation PCL's own EBITDA Margin % has ranged from 16.25 to 30.93 over the past decade. While the company's 10-year median is 20.49 vs. the industry median of 5.00, Bangkok Genomics Innovation PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current EBITDA Margin % of 24.27% is 385.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current EBITDA Margin % is 24.27%, which is 18% above median its own 10-year median of 20.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current EBITDA Margin % of 24.27%. The current EBITDA Margin % is 24.27%, which is 18% above median its 10-year median of 20.49 and 385.4% above the Medical Diagnostics & Research industry median of 5.00. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current EBITDA Margin % is 24.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
